Phase 3 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
"Who might be able to join this trial:
- People who have been diagnosed with fluid build-up in the central part of the eye (called macular edema) linked to diabetes-related eye disease, whether or not they have had previous treatment for this condition.
- People whose vision in the eye being studied falls within a specific range — not too severely impaired and not near-perfect — as measured by a standard eye chart test at two separate appointments before the trial begins.
- People who have had previous treatment must have received at least one injection of a specific type of eye medication (called anti-VEGF) in the past 12 months, and their most recent injection must have been given at least 12 weeks before the initial screening appointment.
Who may not be able to join:
- People whose vision in the eye that is not being studied has fallen below a certain level of severity on a standard eye chart test (confirm with trial site for exact measurements).
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 833-393-7646
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Average change in best corrected visual acuity (BCVA)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.